🚀 Exciting Collaboration Announcement! 🚀
April 28, 2025
We at
Pharmidex have been delighted to collaborate closely with the talented teams at
Apeikon Therapeutics and
King's College London to generate exciting new data in the field of oncology research.
We are proud to share that our collaborative poster will be presented this afternoon at the AACR Annual Meeting 2025 in Chicago! 🇺🇸✨
📄 Check out the poster and learn more here:
https://lnkd.in/e7-TVBB9
A huge thank you to everyone involved for making this project a success, we are looking forward to continuing to push the boundaries of discovery together!
If you're attending AACR, come and visit, we would love to discuss our findings and explore new opportunities for collaboration.
#Pharmidex #AACR2025 #Collaboration #OncologyResearch #DrugDiscovery #TranslationalResearch #Teamwork #Innovation
Pharmidex team are delighted to participate in workshop on "Re-shaping UK life science commercialisation strategy" organised by The Research and Development Society on Wednesday 11th June, at Mereside, Alderley Park. If you are attending, please linkup with our colleague Mo Alavijeh who will be delighted to meet you. Jamie Phadke , Alderley Park #UKlifescience https://lnkd.in/e6uKsRcN
Martin Barrett , Head of Business Development, will attend the symposium on 10–13 June 2025 at Hotel Comwell Borupgaard, Denmark. The event gathers top European scientists to discuss drug discovery. Martin looks forward to connecting with academia, CROs, and pharma to explore collaborations and showcase Pharmidex’s services from in silico to in vivo pharmacology. Attending? Let’s connect! 🔗 https://lnkd.in/ev7TW7WG
We’re excited to announce our involvement in the recent publication: "Anti-Inflammatory Activity of Ensifentrine: A Novel, Selective Dual Inhibitor of PDE3 and PDE4" 📄 https://pubmed.ncbi.nlm.nih.gov/40245851/ 📄 https://www.pharmidex.com/publications-by-pharmidex Dr. Radhakrishnan Venkatasamy , our Senior Scientist in autoinflammatory and immune diseases, co-authored this study highlighting Ensifentrine’s anti-inflammatory potential. This reflects Pharmidex’s commitment to advancing therapies through expert science and collaboration.
